IL-6 pathway in the liver: From physiopathology to therapy (Q26766606)

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

The soluble interleukin-6 receptor is generated by shedding

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

An acute phase protein ready to go therapeutic for sepsis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Opposing roles of gp130-mediated STAT-3 and ERK-1/ 2 signaling in liver progenitor cell migration and proliferation

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Lack of interleukin-6/glycoprotein 130/signal transducers and activators of transcription-3 signaling in hepatocytes predisposes to liver steatosis and injury in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Cholangiocyte senescence by way of N-ras activation is a characteristic of primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Role of interleukin-6 and soluble IL-6 receptor in region-specific induction of astrocytic differentiation and neurotrophin expression.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Hyper-IL-6 gene therapy reverses fulminant hepatic failure.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

The regenerative activity of interleukin-6.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Elevated serum interleukin-6 levels in patients with acute hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Ciliary neurotrophic factor induces acute-phase protein expression in hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

The acute phase response

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Role of IL-6 trans-signaling in CCl₄induced liver damage

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Essential role of neutrophil mobilization in concanavalin A-induced hepatitis is based on classic IL-6 signaling but not on IL-6 trans-signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

NCOA5 haploinsufficiency results in glucose intolerance and subsequent hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Obesity promotes liver carcinogenesis via Mcl-1 stabilization independent of IL-6Rα signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Insulin action in AgRP-expressing neurons is required for suppression of hepatic glucose production.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Adiponectin enhances insulin sensitivity by increasing hepatic IRS-2 expression via a macrophage-derived IL-6-dependent pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

PGRN is a key adipokine mediating high fat diet-induced insulin resistance and obesity through IL-6 in adipose tissue

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

A switch from white to brown fat increases energy expenditure in cancer-associated cachexia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Interleukin-6: Biology, signaling and strategies of blockade

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Hepatic acute phase proteins--regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-κB-dependent signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Hepatocyte senescence predicts progression in non-alcohol-related fatty liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Hepatocyte senescence explains conjugated bilirubinaemia in chronic liver failure.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Bipotential adult liver progenitors are derived from chronically injured mature hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Hepatocellular hyperplasia, plasmacytoma formation, and extramedullary hematopoiesis in interleukin (IL)-6/soluble IL-6 receptor double-transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

The interleukin 6 pathway and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Impaired immune and acute-phase responses in interleukin-6-deficient mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Lack of gp130 expression in hepatocytes attenuates tumor progression in the DEN model

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

NF-kappaB functions as a tumour promoter in inflammation-associated cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

A gp130-Src-YAP module links inflammation to epithelial regeneration

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

A bioactive designer cytokine for human hematopoietic progenitor cell expansion

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Hepatic progenitor cells of biliary origin with liver repopulation capacity

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Interleukin 6: from bench to bedside

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

IL-6 as a keystone cytokine in health and disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Interleukin-6-deficient mice develop mature-onset obesity

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Muscles, exercise and obesity: skeletal muscle as a secretory organ

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Liver regeneration: from myth to mechanism

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

IL-6 biology: implications for clinical targeting in rheumatic disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

gp130 activation is regulated by D2-D3 interdomain connectivity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Soluble receptors for cytokines and growth factors: generation and biological function

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Acute-phase response factor, increased binding, and target gene transcription during liver regeneration.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Combined interleukin 6 and soluble interleukin 6 receptor accelerates murine liver regeneration

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Signal Transducer and Activator of Transcription 3 Protects From Liver Injury and Fibrosis in a Mouse Model of Sclerosing Cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Acute-phase proteins and other systemic responses to inflammation

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Obesity and the metabolic syndrome in children and adolescents

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Sympathetic neurons can produce and respond to interleukin 6

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Distinct role of gp130 activation in promoting self-renewal divisions by mitogenically stimulated murine hematopoietic stem cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6-sIL-6R double transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Murine cardiotrophin-1 stimulates the acute-phase response in rat hepatocytes and H35 hepatoma cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Interleukin-6 Trans-Signaling Regulates Glycogen Consumption After d-Galactosamine-Induced Liver Damage

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Acute phase protein α1-antitrypsin reduces the bacterial burden in mice by selective modulation of innate cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

IL-6: from its discovery to clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Liver regeneration induced by a designer human IL-6/sIL-6R fusion protein reverses severe hepatocellular injury.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Serum C-reactive protein levels in disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

A stress signaling pathway in adipose tissue regulates hepatic insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

A portal blood factor as the humoral agent in liver regeneration

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

1 reference

7 January 2021

Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Interleukin-6: from basic science to medicine--40 years in immunology

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Hepatocellular carcinoma originates from hepatocytes and not from the progenitor/biliary compartment.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Transgenic blockade of interleukin 6 transsignaling abrogates inflammation

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Therapy for myeloproliferative neoplasms: when, which agent, and how?

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Assessment of tocilizumab in the treatment of cancer cachexia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

STAT3 targets the regulatory regions of gluconeogenic genes in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Oncogenic deletion mutants of gp130 signal from intracellular compartments

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Trans-Signaling Is a Dominant Mechanism for the Pathogenic Actions of Interleukin-6 in the Brain

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Ligand/Receptor Signaling Threshold (LIST) Model Accounts for gp130-Mediated Embryonic Stem Cell Self-Renewal Responses to LIF and HIL-6

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Constitutive STAT3 phosphorylation contributes to skeletal muscle insulin resistance in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Deletion of skeletal muscle SOCS3 prevents insulin resistance in obesity

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Liver regeneration after partial hepatectomy: critical analysis of mechanistic dilemmas

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review).

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

IL-6 controls the innate immune response against Listeria monocytogenes via classical IL-6 signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021

IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JHEP.2016.02.004

7 January 2021